Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class A

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S carries a market capitalization of 4.91B, placing it among publicly traded companies globally. Its enterprise value stands at 4.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S has 1.78B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S maintains a current ratio of 1.38, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S recorded 16.43M in income tax expense.

As of the close on October 23, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S's stock has declined approximately 2.66% over the past 52 weeks. The 50-day moving average sits at 2.55, while the 200-day moving average is 3.00.

As of June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S holds 360.79M in cash and equivalents against 13.10M in total debt, resulting in a net debt position of -349.09M. Total book value stands at 875.63M, with working capital of 253.27M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S paid dividends of 0.27 per share.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S's most recent stock split took place on June 30, 2010 with a 1:2 split ratio.